Loading...

Home
Stock
CSTL

CSTL Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

26.640

Open

26.410

VWAP

26.20

Vol

232.54K

Mkt Cap

776.88M

Low

25.822

Amount

6.09M

EV/EBITDA(TTM)

--

Total Shares

29.73M

EV

487.84M

EV/OCF(TTM)

7.58

P/S(TTM)

2.21

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

Show More

Events Timeline

(ET)

2026-02-26

17:00:00

Company Reports Q4 Revenue of $87M Exceeding Expectations

2026-02-26

17:00:00

Castle Biosciences Sees 2026 Revenue of $340M-$350M

2026-01-11 (ET)

2026-01-11

17:20:00

Castle Biosciences Expects 2025 Total Revenue to Exceed $340 Million

2026-01-07 (ET)

2026-01-07

06:50:00

Castellum Re-awarded $49.8M Naval Contract

News

Newsfilter

03-04Newsfilter

Castle Biosciences Presents New Data on Sentinel Lymph Node Positivity Prediction

New Data Presentation: Castle Biosciences will present data on the DecisionDx-Melanoma's i31-SLNB test at the 2026 Society of Surgical Oncology Annual Meeting, aiming to predict sentinel lymph node positivity and further validate the test's significance in clinical decision-making.
Clinical Validation Results: Initial study findings indicate that the test can impact sentinel lymph node biopsy decisions and identify low-risk metastatic patients, thereby optimizing patient management strategies in line with National Comprehensive Cancer Network risk thresholds.
Personalized Risk Assessment: The i31-SLNB algorithm integrates the 31-GEP score with key clinicopathologic factors to provide a more precise risk estimation than staging alone, supporting personalized shared decision-making and enhancing patient treatment confidence.
Broad Application Foundation: DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and has been ordered more than 220,000 times since launch, demonstrating its association with improved patient survival and highlighting its importance in managing cutaneous melanoma.

Newsfilter

03-03Newsfilter

Castle Biosciences to Celebrate Grand Opening of New Headquarters

New Headquarters Opening: Castle Biosciences will host a grand opening celebration for its new headquarters on March 24, 2026, marking the completion of its investment in Friendswood, with local and national officials expected to attend, highlighting the company's commitment to the community.
Facility Features: The new 23-acre headquarters includes modern, flexible workspaces and advanced technology infrastructure designed to support the company's ongoing growth and innovation, enhancing employee experience and collaboration.
Sustainability Focus: The building incorporates energy-efficient systems and storm-rated design elements to enhance sustainability and resilience, reflecting the company's commitment to environmental responsibility while providing amenities like a fitness center and outdoor collaboration spaces for employees.
Community Engagement: As one of the largest publicly traded companies in Galveston County with $344 million in revenue in 2025, Castle Biosciences has a long history of supporting the Friendswood community, dedicated to improving patient lives and fostering local development.

seekingalpha

02-27seekingalpha

Castle Biosciences Reports Strong Q4 2025 Earnings with Revenue Growth

Significant Revenue Growth: Castle Biosciences reported fourth-quarter revenue of $87 million and full-year revenue of $344.2 million, exceeding expectations and demonstrating sustained strong performance across core revenue drivers.
Surge in Test Report Volume: The total test report volume from core revenue drivers increased by 37% to 105,053, with TissueCypher test report volume growing by 86%, indicating the company's strengthening competitive position in the market.
Successful Product Launch: The AdvanceAD-Tx test saw over half of the initial 150 dermatological accounts placing orders within the first five weeks of clinical availability, with early results exceeding expectations, suggesting strong future market potential.
Optimistic Future Outlook: Management guided total revenue for 2026 to be between $340 million and $350 million, primarily driven by continued growth in TissueCypher, reflecting the company's confidence and strategic planning for future market opportunities.

seekingalpha

02-25seekingalpha

Castle Biosciences to Announce Q4 Earnings on February 26

Earnings Announcement Schedule: Castle Biosciences (CSTL) is set to announce its Q4 2023 earnings on February 26 after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
Earnings Expectations: The consensus EPS estimate stands at -$0.26, reflecting a significant year-over-year decline of 181.3%, indicating potential profitability challenges that may affect investor sentiment.
Revenue Forecast Changes: The revenue estimate is projected at $80.31 million, down 6.9% year-over-year; however, the company has surpassed revenue estimates 100% of the time over the past year, showcasing its resilience in the market.
Estimate Revision Trends: Over the last three months, EPS estimates have seen four upward revisions and no downward adjustments, while revenue estimates experienced five upward revisions and one downward, suggesting analysts' growing confidence in the company's future performance.

Newsfilter

02-19Newsfilter

Castle Biosciences Publishes New Study Results

Clinical Validation Study: Castle Biosciences published a prospective multicenter clinical validation study in the Journal of the American Academy of Dermatology, demonstrating that the AdvanceAD-Tx test can identify moderate-to-severe atopic dermatitis patients who are more likely to achieve faster clinical responses when treated with JAK inhibitors, highlighting the test's significance in personalized treatment.
Significant Efficacy Improvement: The study found that approximately 30% of patients treated with JAK inhibitors were identified as JAK Inhibitor Responders, with these patients being 5.5 times more likely to achieve at least 90% improvement in the Eczema Area and Severity Index (EASI-90) within three months compared to those treated with Th2-targeted therapies, indicating a substantial enhancement in treatment outcomes.
Quality of Life Enhancement: Among JAK Inhibitor Responders, 45.5% reported

Fool

AIGH Capital Fully Exits Lumen Technologies Stake

Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.

Wall Street analysts forecast CSTL stock price to rise

5 Analyst Rating

Wall Street analysts forecast CSTL stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

41.00

Averages

47.20

High

52.00

Current: 0.000

Low

41.00

Averages

47.20

High

52.00

Baird

Outperform

maintain

$41 -> $44

AI Analysis

2026-02-27

Reason

Baird

Price Target

$41 -> $44

AI Analysis

2026-02-27

maintain

Outperform

Reason

Baird raised the firm's price target on Castle Biosciences to $44 from $41 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results and an outlook above consensus.

KeyBanc

Paul Knight

maintain

$36 -> $50

2026-01-29

Reason

KeyBanc

Paul Knight

Price Target

$36 -> $50

2026-01-29

maintain

Reason

KeyBanc analyst Paul Knight raised the firm's price target on Castle Biosciences to $50 from $36 and keeps an Overweight rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CSTL

Unlock Now

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -26.15, compared to its 5-year average forward P/E of -16.75. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-16.75

Current PE

-26.15

Overvalued PE

-3.34

Undervalued PE

-30.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-13.18

Current EV/EBITDA

51.39

Overvalued EV/EBITDA

4.79

Undervalued EV/EBITDA

-31.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.47

Current PS

3.52

Overvalued PS

10.81

Undervalued PS

0.12

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best ai stock to buy

Intellectia · 102 candidates

Revenue 5yr Cagr: >= 18Eps 5yr Cagr: >= 12Pe Ttm: <= 35

Ticker

Name

Market Cap$

eToro Group Ltd

2.56B

Brookfield Wealth Solutions Ltd

14.12B

Civitas Resources Inc

2.32B

Futu Holdings Ltd

23.11B

Dlocal Ltd

3.98B

GigaCloud Technology Inc

1.47B

list a stock with 10x potential

Intellectia · 10 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Weekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Figs Inc

1.90B

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

Xpel Inc

1.52B

Arhaus Inc

1.49B

GigaCloud Technology Inc

1.47B

stocks that will rise the most by 2026

Intellectia · 17 candidates

Revenue 5yr Cagr: >= 25Eps 5yr Cagr: >= 25Pe Ttm: <= 25Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

Monolithic Power Systems Inc

51.50B

Futu Holdings Ltd

23.11B

Genmab A/S

20.30B

Super Micro Computer Inc

19.25B

Kaspi.kz AO

14.51B

Kinsale Capital Group Inc

9.43B

which stocks should short sell

Intellectia · 2 candidates

Short Ratio: LessThan10PctBeta: HighRiskRsi 14: >= 60Month Price Change Pct: $-100.00 - $0.00

Ticker

Name

Market Cap$

Castle Biosciences Inc

1.20B

Standard BioTools Inc

630.69M

small cap stocks anticipating 20-30% growth

Intellectia · 8 candidates

Market Cap: 300.00M - 2.00BRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

GigaCloud Technology Inc

1.47B

Vital Farms Inc

1.22B

Castle Biosciences Inc

1.20B

LuxExperience BV

1.14B

Nuveen Churchill Direct Lending Corp

677.59M

Tiptree Inc

654.35M

small cap , growth

Intellectia · 18 candidates

Market Cap: 300.00M - 2.00BRevenue 5yr Cagr: >= 10Eps 5yr Cagr: >= 10Pe Ttm: <= 30Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

Costamare Inc

1.91B

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

GigaCloud Technology Inc

1.47B

Vital Farms Inc

1.22B

Opera Ltd

1.21B

Next stock that will 100x

Intellectia · 7 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20

Ticker

Name

Market Cap$

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

GigaCloud Technology Inc

1.47B

Opera Ltd

1.21B

Castle Biosciences Inc

1.20B

Inmode Ltd

892.51M

Best stocks to 1000x in future

Intellectia · 21 candidates

Market Cap: <= 5.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20

Ticker

Name

Market Cap$

Crocs Inc

4.43B

St Joe Co

3.75B

Paymentus Holdings Inc

3.63B

ACM Research Inc

3.47B

Fortuna Mining Corp

3.30B

Banc of California Inc

3.28B

Best stock with future potential 100x

Intellectia · 7 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20

Ticker

Name

Market Cap$

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

GigaCloud Technology Inc

1.47B

Opera Ltd

1.21B

Castle Biosciences Inc

1.20B

Inmode Ltd

892.51M

Whales Holding CSTL

Summit Partners Public Asset Management, LLC

Portolan Capital Management, LLC

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 26.13 USD — it has decreased -1.77

What is Castle Biosciences Inc (CSTL)'s business?

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

What is the price predicton of CSTL Stock?

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

Castle Biosciences Inc revenue for the last quarter amounts to 87.01M USD, increased 0.81

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

Castle Biosciences Inc. EPS for the last quarter amounts to -0.08 USD, decreased -125.81

How many employees does Castle Biosciences Inc (CSTL). have?

Castle Biosciences Inc (CSTL) has 883 emplpoyees as of March 12 2026.

What is Castle Biosciences Inc (CSTL) market cap?

Today CSTL has the market capitalization of 776.88M USD.